Jam City and Disney Announce Multi-Year Mobile Games Development Partnership
Jam City, a leader in mobile entertainment, today announced a multi-year mobile games development partnership with Disney that includes Jam City taking over Disney’s popular mobile game, Disney Emoji Blitz. Members of Disney’s Glendale Games Studio will join Jam City and continue to operate and grow Disney Emoji Blitz as part of the Jam City team. Jam City will also have the right to develop new mobile games based on iconic characters and stories from Pixar and Walt Disney Animation Studios. The first game Jam City and Disney plan to develop is a mobile game based on Disney Animation’s Frozen sequel.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181114005011/en/
Jam City and Disney Announce Multi-Year Mobile Games Development Partnership (Graphic: Business Wire)
“Jam City is proud to be teaming with Disney,” said Chris DeWolfe, co-founder and CEO of Jam City. “Disney is the world’s leader in beloved characters and brands that have engaged generations of fans for decades. Jam City’s leadership in mobile entertainment based on iconic entertainment IP, makes our company an ideal partner to develop a lineup of new mobile games with Disney’s most popular franchises.”
“While our licensing business for Disney Animation and Pixar games has grown over the last year and we have several top developers creating Disney games, this deal with Jam City represents a significant long-term opportunity for our games business and for the future slate of Disney and Pixar games,” said Kyle Laughlin, Senior Vice President of Games and Interactive Experiences at Disney. “We can’t wait to see how Jam City and the incredibly talented team behind Disney Emoji Blitz will grow the already successful game and franchise, and how Jam City will bring their global reach and expertise in developing successful, enduring mobile games to the upcoming titles.”
Through Disney Emoji Blitz, players collect and match hundreds of Disney Animation, Pixar and Star Wars emojis. The game’s players also earn prizes, complete missions, and discover new emoji characters from Disney Animation’s Wreck-It Ralph, Mickey Mouse & Friends, Disney Villains, Pixar's Toy Story and more. Disney Emoji Blitz engages users by combining a unique match-3 blitz game with a deep emoji collection mechanic.
Disney Emoji Blitz is currently available on the App Store and Google Play. Other free-to-play mobile titles developed under the Jam City and Disney agreement will be available worldwide on the App Store and Google Play.
About Jam City
Jam City is a leader in mobile entertainment, providing unique and deeply engaging games that appeal to broad global audiences. Jam City was founded in 2009 by MySpace co-founder and CEO Chris DeWolfe and former 20th Century Fox executive Josh Yguado. Jam City is the creative powerhouse behind some of the highest grossing and most enduring social gaming franchises for mobile, including Cookie Jam (Facebook “Game of the Year” winner) and Panda Pop. Jam City is the go-to studio for Hollywood, having developed immersive, narrative rich mobile games around iconic entertainment brands including Harry Potter, Family Guy and Marvel Avengers. Jam City has studios in Los Angeles (HQ), San Francisco, San Diego, Bogotá and Buenos Aires. The Jam City team is known for its creative excellence and technological innovation in key areas including storytelling, data science and audience insights.
About Disney Parks, Experiences and Consumer Products
Disney Parks, Experiences and Consumer Products is the business segment of The Walt Disney Company (NYSE:DIS) that brings the magic of Disney's stories, characters and franchises into the daily lives of families and fans around the world to create memories that last a lifetime. The company's iconic travel and leisure businesses include six resort destinations in the United States, Europe, and Asia; a top-rated cruise line; a luxurious family beach resort in Hawaii; a popular vacation ownership program; and an award-winning guided family adventure business. Disney's global consumer products operations include the world's leading licensing business; the world's largest children's print publisher; Disney Store locations around the world; and the shop Disney e-commerce platform. These experiences are created by Walt Disney Imagineering, the innovative force responsible for overseeing the segment's world-class products and experiences — from immersive lands to interactive toys, and everything in between.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20181114005011/en/
Contact information
Jam City
Sarah Ross, 310-924-1404
sarahr@jamcity.com
or
Disney
Amanda
Gonzalez, 415-623-1159
amanda.gonzalez@disney.com
About Business Wire
Business Wire(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release
HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY
Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release
Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio
Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)
Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release
Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com
Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release
Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new